Long Island Vitreoretinal Consultants Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT00440609
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Philip J. ferrone, M.D.

Active Ingredients

Drugs in Phase 2 Trials (1)

ranibizumab (lucentis) (2 trials)

Drugs in Other Trials (2)

bevacizumab (avastin) (2 trials)

dexamethasone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 2)

Macular Edema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3